Novo Holdings acquires biopharma company Paratek for $462m
Paratek’s lead product, Nuzyra, is currently marketed in the US as an oral and intravenous antibiotic.

Paratek’s lead product, Nuzyra, is currently marketed in the US as an oral and intravenous antibiotic.
The neurotech will receive the investment in Series B equity financing round to invest in Alzheimer’s disease research.
The pharmaceutical industry continues to be a hotbed of innovation, with activity driven by the evolution of new treatment paradigms,...
EMA CHMP recommends approval for Moderna’s updated Covid-19 vaccine
Corporate sustainability needs ESG standards and tools
FDA approves Pfizer-BioNTech’s Omicron XBB.1.5-adapted Covid-19 vaccine
Alexion and Verge enter AI-powered drug discovery deal